BeyondSpring is trading 6.55% down at $0.72, with no clear catalyst identified for the October 1 decline.

  • The FDA Fast Track designation and Biolin transaction were announced September 29, so they are prior news, not an evident explanation.
  • Broader market context was modestly positive, not a clear same-direction explanation.
  • Sharp recent swings add context but do not identify a cause.